Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05413421 · ClinicalTrials.gov registry record · Phase 1

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

A Phase 1 study of Metastatic Prostate Cancer, sponsored by ORIC Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
250
Enrollment target
20
Study locations

NCT05413421 is a Phase 1 study of Metastatic Prostate Cancer that is actively recruiting participants, run by ORIC Pharmaceuticals. The registered enrollment target is 250 participants, above the 180-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05413421, a Phase 1 study of Metastatic Prostate Cancer, is actively recruiting participants, sponsored by ORIC Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
250 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

Conditions Studied

Metastatic Prostate Cancer

Interventions

  • DRUG ORIC-944
  • DRUG Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
  • DRUG Apalutamide (Erleada™) 60 mg or 240 mg tablets
  • DRUG Darolutamide (Nubeqa®) 300 mg tablets
  • DRUG Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets

Study Locations (20)

Illinois

  • Illinois Cancer Specialists - Arlington Heights
  • Comprehensive Urologic Care - Lake Barrington

Maryland

  • Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland - Baltimore
  • Maryland Oncology Hematology - Silver Spring

Pennsylvania

  • MidLantic Urology - Bala-Cynwyd
  • Keystone Urology Specialists - Lancaster

Texas

  • Amarillo Urology Research - Amarillo
  • Urology Clinics of North Texas - Dallas

Virginia

  • Virginia Oncology Associates - Fairfax
  • Virginia Cancer Specialists - Norfolk

Colorado

  • Rocky Mountain Cancer Center - Colorado Springs

Florida

  • South Florida Oncology and Hematology - Plantation

Indiana

  • First Urology - Jeffersonville

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2022-06-01
Est. Completion 2026-09
Phase Phase 1

Sponsor

ORIC Pharmaceuticals

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05413421

The ClinicalTrials.gov registry entry for NCT05413421 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 180-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (39% higher). The listed sponsor is ORIC Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which ORIC-944 is the first listed.

NCT05413421 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Illinois, Maryland, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05413421 about?

NCT05413421 is a clinical study titled "Study of ORIC-944 in Patients With Metastatic Prostate Cancer". The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

What is the current status of trial NCT05413421?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2022-06-01. Estimated completion is 2026-09.

What conditions does trial NCT05413421 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer.

What interventions are being tested in trial NCT05413421?

The interventions under investigation include: ORIC-944 (DRUG), Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets (DRUG), Apalutamide (Erleada™) 60 mg or 240 mg tablets (DRUG), Darolutamide (Nubeqa®) 300 mg tablets (DRUG), Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets (DRUG).

Who is sponsoring clinical trial NCT05413421?

This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05413421 being conducted?

This trial has 20 study locations across Colorado, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.